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Amyloid-beta (Aβ) in Alzheimer’s disease (AD) appeared to be a promising target
for disease-modifying therapeutic strategies like passive immunotherapy with anti-Aβ
monoclonal antibodies (mAbs). Biochemical markers in cerebrospinal fluid (CSF) include
alterations of Aβ that allow the diagnosis of AD. Biomarker strategies, such as the levels
of Aβ in CSF and plasma, currently play an important role in early clinical trials for AD.
Indeed, these strategies have a relevant impact on the outcome of such studies, since
the biomarkers are used to monitor the bioactivity of anti-Aβ mAbs. The clinical trials of
Solanezumab were mainly based on the readout of Aβ levels in CSF and plasma, whereas
those of Bapineuzumab were based on cognition; however, little is known about the
mechanisms altering these biomarker levels, and no biomarker has yet been proven to
be a successful predictor for AD therapy. In addition, the Aβ biomarkers allow for the
determination of free and bound anti-Aβ mAb in order to monitor the available amount of
bioactive drug and could give hints to the mechanism of action. In this review, we discuss
clinical Aβ biomarker data and the latest regulatory strategies.
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Aβ-AGGREGATES AND THEIR IMPLICATIONS ON
IMMUNIZATION
With about 70% of all cases, Alzheimer’s disease (AD) is the most-
common form of dementia (Alzheimer’s Disease International,
2009) and countries in demographic transition will experience
the greatest growth. AD is defined as a multifactorial disease
with the pathogenic cerebral deposition of the aggregated pro-
teins Amyloid-β (Aβ) and hyper-phosphorylated tau (phospho-
tau). Despite the well-accepted pathogenic role of Aβ (Selkoe,
2001), the underlying pathogenic mechanism is still elusive
(Broersen et al., 2010). Aβ-aggregates—majorly derived from
Aβ40 and Aβ42—are generated from amyloid precursor pro-
tein by sequential proteolysis (Haass and Selkoe, 2007) followed
by self-association from monomeric to soluble oligomeric and
protofibrillar Aβ. Protofibrillar Aβ further aggregates into insol-
uble Aβ-fibrils and deposits in the brain as amyloid plaques.
Since the number of these plaques does not correlate well with
the severity of dementia (Terry, 2006)—as opposed to soluble
Aβ-aggregates (McDonald et al., 2010)—the amyloid hypothe-
sis has been reformulated, positioning soluble Aβ aggregates as
hallmark in AD pathology (Walsh and Selkoe, 2007; Broersen
Abbreviations: aa, amino acid; Aβ, amyloid-beta; AβO, Aβ oligomers; AD,
Alzheimer’s disease; ADAS-Cog, Alzheimer’s Disease Assessment Scale-cognitive
subscale; ADDLs, Alzheimer derived diffusible ligands; ADNI, Alzheimer’s
disease neuroimaging initiative; AFM, atomic force microscopy; ApoE4,
ApolipoproteinE4; CSF, cerebrospinal fluid; DAD, disability assessment for
dementia; EMA, European Medicine Agency; FDA, food and drug administration;
J&J, Johnson&Johnson; LRP, low density lipoprotein receptor-related protein; MRI,
magnetic resonance imaging; PET, positron emission tomography; phospho-tau,
hyperphosphorylated tau; PK, pharmacokinetic; SDS-PAGE, sodium dodecyl sul-
fate polyacrylamide gel electrophoresis; TEM, transmission electron microscopy.
et al., 2010). A plethora of different Aβ-species with overlapping
size and morphology have been described (Broersen et al., 2010;
Benilova et al., 2012): Aβ-dimers (Shankar et al., 2008; O’Nuallain
et al., 2010), low-molecular weight oligomers comprising dimeric
to tetrameric Aβ (Walsh et al., 2005), pentamers and hexam-
ers (Ahmed et al., 2010), dodecameric Aβ56* (Lesne et al.,
2006; Reed et al., 2011), globulomers (Barghorn et al., 2005),
Aβ-oligomers (Kayed et al., 2003), Alzheimer-derived diffusible
ligands (ADDLs; Lambert et al., 1998), protofibrils (Walsh et al.,
1999), and amylospheroids (Hoshi et al., 2003). Although, the
size andmolecular weight of these Aβ-species have predominantly
been used for differentiation, the peptide source, either synthetic
or endogenous, and the applied methods for characterization—
e.g., SDS-PAGE, TEM, AFM, Ultracentrifugation—hamper a
direct comparison (Moreth et al., 2013). Despite the pathological
relevance of endogenous Aβ-species, low protein concentrations
and protein heterogeneity elude a precise characterization of the
molecular identity. The synthetic Aβ-aggregate is applicable to
a more-precise characterization, but still retains limited rele-
vance, since the variety of reported Aβ-aggregates has yet to be
proven to be present in AD brain. Furthermore, the identification
of Aβ-aggregates is hampered owing to their meta-stability and
the ability for inter-conversion in different aggregation pathways
(Moreth et al., 2013), which was also mentioned by Bitan et al.
(2005). This is of great importance for immunization, since the
fate of the pre-aggregated Aβ is elusive after injection.
OCCURRENCE OF Aβ SPECIES IN PLASMA AND CSF
From a set of upcoming biomarkers (Fagan and Perrin, 2012), the
most-established biomarkers for AD diagnosis in cerebrospinal
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fluid (CSF) are still the determination of Aβ42, total-Tau and
phospho-Tau181 (Di Carlo et al., 2012). Only a combination of
these three CSF biomarkers increases the validity of the diagno-
sis with a combined sensitivity of 95% (Blennow et al., 2010).
In AD, CSF-Aβ42 is significantly decreased, which is believed
to be due to decreased clearance of aggregated Aβ42 from the
brain. The Aβ40 levels seem to be constant and therefore the
increased Aβ42/Aβ40 ratio has been suggested to improve early
AD-diagnosis. However, this is still controversial and for plasma-
derived Aβ reports are even more contradictory (Zetterberg,
2008; Zetterberg et al., 2010). To mention the prefibrillar Aβ-
aggregates as the prime toxic agents in AD, one might address
these as potential biomarkers. However, there is still a lack of a
robust method for the detection of larger Aβ-aggregates in vivo
(e.g., ADDL, Aβ-oligomers). Some recent reports showed meth-
ods for Aβ-aggregate detection based on ELISA, IP western
blotting and Aβ-aggregate capture assays. All of these meth-
ods are based on conformation-specific antibodies, which do
not detect monomeric or fibrillar, but rather the prefibrillar
aggregates (Funke et al., 2009), even though the most relevant
Aβ-aggregate for AD diagnosis is still elusive. Furthermore, based
on the described meta-stability of Aβ-aggregates (Moreth et al.,
2013), it might be misleading to focus on a single aggregate
species if the whole spectrum of aggregates from the dimer up
to protofibrillar Aβ are present in the brain and of importance in
AD-progression.
PLASMA AND CSF Aβ AS BIOMARKERS TO MONITOR
PASSIVE ANTI-Aβ IMMUNOTHERAPY CLINICAL STUDIES
Aβ has a complex pharmacokinetic profile, as it is permanently
produced in brain as well as in the periphery, and transported
back and forth between both pharmacokinetic compartments
(Zlokovic et al., 1993; Ghersi-Egea et al., 1996; Shibata et al.,
2000). Soluble Aβ is either degraded by proteases (Iwata et al.,
2005), transported via the blood-brain barrier by receptors like
LRP (Sagare et al., 2007), RAGE (Deane et al., 2003), and P-
glycoprotein (Ito et al., 2006), or aggregates to multimers and
plaques. Likewise, plaque Aβ is in steady-state equilibrium with
soluble Aβ (Kawarabayashi et al., 2001). Finally, Aβ is rapidly
eliminated by hepatic and renal degradation (Ghiso et al., 2004).
PET scanning with the Pittsburgh compound (PiB) detects fibril-
lar Aβ. CSFAβ42 and PETmeasures of fibrillar Aβ are significantly
inversely correlated with each other, likely to reflect Aβ deposition
in the brain (Fagan et al., 2006).
Proteins in plasma, like antibodies that capture soluble Aβ, are
capable of sequestering soluble forms of Aβ from their bound and
circulating forms. Total Aβ plasma levels will therefore increase
while free Aβ levels reduce due to the longer half-life of protein-
complexed Aβ [see Figure 1A; (Park et al., 2012)]. The elimi-
nation of the Aβ-protein complex is according to the complex’s
half-life, which is rather long in the case of FcRn-recycled mon-
oclonal antibodies (mAbs). Complexed Aβ is predictably not
transported across the blood brain barrier, does not form mul-
timers, and influences the equilibrium between soluble Aβ and
plaque Aβ that appears to result in improved clearance of cere-
bral Aβ, e.g., CSF Aβ. The Aβ-binding proteins should have
an affinity to Aβ high enough to compete with endogenous
Aβ-binding proteins and transporters. Free Aβ drops rapidly
after Aβ is sequestered, but due to its rapid synthesis in various
tissues, it is restored to basal endogenous levels rather quickly
(Barten et al., 2005).
Peripherally-administered mAbs that sequester soluble Aβ
result in an increase of plasma Aβ (DeMattos et al., 2002) that
is correlated to its affinity; some mAbs are even capable of reduc-
ing CSF Aβ (Mavoungou and Schindowski, 2013). Several studies
used these biomarkers as clinical strategy (Table 1). Solanezumab
caused a sharp, sustained, and dose-dependent increase of plasma
Aβ1−40 and Aβ1−42 (Farlow et al., 2012). CSF Aβ1−40 and Aβ1−42
increased in the mild to moderate AD patients with 0.1% of
plasma levels of Solanezumab found in the CSF. The rise in level
of total Aβ in plasma and CSF is assumed to be related to tar-
get engagement (Strobel and Bowman Rogers, 2012). Free CSF
Aβ was determined by protein G sepharose immunoprecipita-
tion to deplete immunoglobins and subsequent ELISA (Farlow
et al., 2012). Therefore, this method was used for CSF samples
only, since immunoglobulin plasma concentrations are too high
for this method. In a rather small cohort of patients, free CSF
Aβ1−40 decreased with treatment, while free Aβ1−42 did not. It
is suspected that the higher amount of free CSF Aβ1−42 is related
to the dissolution of plaques that were mainly composed of Aβ42.
However, PiB scans of another subcohort showed no signifi-
cant change between the groups, although treated patients with
mild AD had a trend toward less amyloid, this lacked statistical
significance (Matthews and Bader, 2012).
The clinical biomarker data from Bapineuzumab are more
difficult to interpret, due to the fact that Bapineuzumab binds
both soluble and plaque Aβ, and the methodological strategy is
rather unclear. Aβ1−40 and Aβx−42 were detected by a sandwich
ELISA using 4G8 for capture and a C-terminal mAb for detection
(Figure 1B). 4G8 does not interfere with Bapineuzumab bind-
ing (Johnson-Wood et al., 1997; Clarke and Shearman, 2000).
Interestingly, Aβ1−42 was determined with an ELISA using 3D6
as capture. 3D6 is the parental molecule of Bapineuzumab and
therefore these two mAbs compete with each other when bind-
ing Aβ. Consequently, Bapineuzumab-Aβ complexes in CSF will
predictably not be detected in this assay, though according to
PK data Bapineuzumab occurs in CSF with 0.3% incidence of
plasma levels (Blennow et al., 2012). Hence, the clinical data
reveal no changes in CSF Aβ1−42 levels with Bapineuzumab
treatment, while Solanezumab treatment revealed an increase
in Aβ1−42 detected with the C-terminal mAb 21F12 and the
N-terminal 3D6. Moreover, to avoid signal suppression due to
steric hindrance, the authors of the Solanezumab study spiked
an excess of Solanezumab in the assay buffer (Farlow et al.,
2012). Furthermore, Bapineuzumab treatment decreased CSF
phospho-tau (Salloway et al., 2012; Sperling et al., 2012). Like
Solanezumab, Bapineuzumab was not active on patient’s cog-
nition and activities of daily living unless subsequent post-test
of subcohorts were considered for re-analysis (Salloway et al.,
2009; Lilly, 2012; Matthews and Bader, 2012). In summary, both
antibodies engaged their target, but they hardly improved clin-
ical signs (Strobel and Bowman Rogers, 2012). Bapineuzumab’s
clinical development was discontinued for AD in 2012 (Johnson
& Johnson, 2012), AAB-003/PF-0523681 an engineered 3D6
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FIGURE 1 | (A) Plasma Aβ levels after treatment with an Aβ sequestering
compound. Anti-Aβ mAbs capture soluble Aβ and form Aβ-mAb
complexes, which have a much longer half-life than free Aβ alone.
Therefore, total Aβ (i.e., free and bound) plasma levels rise while free Aβ
levels drop rapidly but return rather quickly to normal levels due to its
rapid synthesis in many tissues. (B) Binding sites on Aβ1−42 of
therapeutic and diagnostic mAbs. Adapted from Johnson-Wood et al.
(1997); Clarke and Shearman (2000).
replaced Bapineuzumab in the sponsor’s pipeline (Pfizer, 2013).
Dose-dependent plasma total Aβ increases were reported from
GSK933776 and Crenezumab with decreased free plasma Aβ
levels (GlaxoSmithKline, 2011; Adolfsson et al., 2012).
THE IMPORTANCE OF AN APPROPRIATE BIOMARKER
STRATEGY FOR AD
In an ideal world with a successful anti-AD therapy, the detection
of AD biomarkers should indicate appropriate patient selection
likely to derive therapeutic benefit. The EMA tried first to get
closer to this ideal world, at least from the regulatory side, and
introduced research diagnostic criteria that added specificity to
the prevailing concept of mild cognitive impairment (Dubois
et al., 2007). This set the stage for new types of trials (Strobel
and Bowman Rogers, 2012). The criteria are closer to the dis-
ease, combining amild but measurablememory impairment with
a biomarker change. The EMA considered firstly that a pathologi-
cal signature based on CSF Aβ42 and phospho-tau was acceptable
for identifying prodromal-stage patients who are at risk of devel-
oping AD (European Medicines Agency, 2011b), secondly, using
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Table 1 | Clinical effects of anti-Aβ mAbs on CSF and plasma Aβ, adapted from Mavoungou and Schindowski (2013).
Study/cohort Subcohort size for
biomarker evaluation
Evaluated
biomarker
Clinical effect of treatment
on biomarker
Clinical effect on
cognition
PK data of mAb References
BAPINEUZUMAB (HUMANIZED 3D6)
201 Phase II Placebo: n = 14
BAPI: n = 20
CSF Aβx−42
Total CSF tau
CSF phospho-tau
No changes
No changes
Trend to reduction
(p = 0.056)
In small cohort
6% less loss of
ADAS-Cog scores
after 18 months
Approximately
0.3%
CSF-plasma ratio
Salloway et al.,
2009
Phase II:
pooled 201
and 202
Placebo: n = 19
BAPI: n = 26–27
CSF Aβ1−40
CSF Aβx−42
CSF Aβ1−42
Total CSF tau
CSF phospho-tau
No changes
Decrease from baseline
No changes
No changes
Reduction (p = 0.03)
Not determined Not determined Blennow et al.,
2012
Phase III: 301
(ApoE4
carrier)
Placebo: n = 77
0.5mg/kg: n = 47
1.0mg/kg: n = 54
CSF phospho-tau
CSF phospho-tau
No changes at 0.5mg/kg
Reduction at 1.0mg/kg
In a subcohort of
mild cases at
1.0mg/kg ∼30%
less loss of DAD
scores after 18
months
Not determined Salloway et al.,
2012
Phase III: 302
(ApoE4 non-
carrier)
Placebo: n = 85
0.5mg/kg: n = 127
CSF phospho-tau Reduction at 0.5mg/kg No effect on
cognition after 18
months, even not
for mild cases
Not determined Sperling et al.,
2012
SOLANEZUMAB (HUMANIZED m266)
Phase II Placebo: n = 8;
SOLA: n = 10–11 per
dose group
CSF total Aβ40
CSF total Aβ42
CSF free Aβ40
CSF free Aβ42
Plasma total Aβ40
Plasma total Aβ42
Increase at high dose
Increase at high dose
Decrease at high dose
Increase at high dose
Dose-dependent increase
Dose-dependent decrease
No significant
cognitive benefit
on the ADAS-cog
score over after
12-weeks
0.1%
CSF-plasma ratio
Farlow et al., 2012
GSK933776 (DISCONTINUED FOR AD)
Phase I Placebo: n = 14;
GSK933776: n = 3–6
per dose group
Plasma total Aβ
Plasma free Aβ
CSF Aβ1−38
tau/phospho-tau
Dose-dependent increase
Dose-dependent decrease
Increase at the highest dose
No changes
Not determined >0.2%
CSF-plasma ratio
GlaxoSmithKline,
2011
CRENEZUMAB (MABT5102A)
Phase I MABT: n = 25–31 per
regime group
Plasma total Aβ40
Plasma total Aβ40
Dose-dependent increase
Dose-dependent increase
Not determined Not determined Adolfsson et al.,
2012
hippocampal volume (European Medicines Agency, 2011a), and
thirdly, using amyloid PET as a biomarker to enrich pre-dementia
trials (European Medicines Agency, 2011c). Likewise, the FDA
revised its criteria as well. Nevertheless, evidence is needed
that a surrogate marker predicts a subsequent clinical outcome.
Qualifying disease- and disorder-specific biomarkers for AD can
still be considered “exploratory” from a regulatory point of view,
therefore making an accurate validation and qualification ques-
tionable. Nevertheless, biomarkers, in particular those appropri-
ate to guide selection of patients for clinical trials as well as
those used as surrogate endpoint for drug efficacy, have reached
the status of “probable valid biomarker” within the scope of
investigation drugs along with an effective clinical trial strategy.
In conclusion, the results show that CSF biomarkers are bet-
ter predictors of progression to AD than plasma Aβ isoforms
(Hansson et al., 2010).
Florbetapir, which binds Aβ plaques like PiB, was fast-track
reviewed by the FDA and is currently the first granted and there-
fore qualified imaging agent for clinical use (Food and Drug
Administration, 2012a). Following the results of the evalua-
tion, even though a positive scan indicates moderate to frequent
plaques, a positive Florbetapir scan is not AD specific, indicat-
ing that it is not appropriate to establish an accurate diagnosis
of AD (Food and Drug Administration, 2012b). In fact, nobody
currently knows why cognitively normal people accumulate Aβ
in their brains, and what that might mean for their future brain
health. The AD Neuroimaging Initiative (ADNI) belongs to one
of the instruments to gain more information on the disease by
means of PET and MRI linked to genetic disposition, cogni-
tive impairment as well as CSF and plasma biomarkers. The use
of such information obviously is crucial to set future clinical
designs for AD (Food and Drug Administration, 2012a) but also
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as prophylactic examination for physicians in case of genetic pre-
disposition for AD. On the other hand, exploring a set of imaging
and biochemical biomarkers helps to develop regulatory guide-
lines to change diagnostic criteria, their validation and finally to
support the potential use of biomarkers in different stages of drug
development.
While the expressed view is that CSF biomarkers indicate
the pathologic processes underlying AD, it is also important to
keep in mind that specific genotypes like ApoE4 and presenilin
mutations affect the degree of pathological change. Therefore,
using pharmacogenetics will enrich clinical drug development.
From the presented data it seems that use of CSF markers is an
unavoidable step for a correct and early diagnosis. However, the
data reported show only the positive results, with no negative
comments or discussion on potential pitfalls. Uncritical sup-
port without showing areas of uncertainty or controversy could
be misleading, in helping to improve the design of subsequent
randomized controlled clinical trials. The hazard ratio in lon-
gitudinal studies shows an extremely large confidence interval,
which is not that supportive for the utility of monitoring. The
specifications of the confidence interval for such a multifacto-
rial disease like AD might be nowadays too tight in the light of
the recent findings about the disease. That means it is under-
standable that the confidence interval cannot be met for most
of the cases. A combination of biomarkers to boost the sen-
sitivity and reliability for tracking AD progression at different
stage and widening the current specification limits with respect
to confidential interval would better match with the variability of
the results.
CONCLUSION
To summarize, Aβ-aggregates reveal a remarkable metastabil-
ity and the ability for reorganization within different aggregate
equilibria. One might assume that the whole spectrum of pre-
fibrillar Aβ-aggregates is of relevance in AD. Thus, targeting one
specific species of Aβ with immunotherapy and using Aβ as
preclinical and clinical biomarker is based on tentative, though
countless data that apparently do not reflect the clinical real-
ity. Therefore, the clinical biomarker data from the phase II and
III studies of the most-advanced anti-Aβ mAbs are not appro-
priate to predict the cognitive outcome, even though the results
show that CSF Aβ appears to be more relevant than plasma
Aβ. This stresses the urgent need to understand the molecular
basis of AD and to find adequate surrogate biomarkers. From
a regulatory point of view, the approval of a highly-innovative
active substance for the treatment for AD still remains a chal-
lenge. Although biomarker strategies have been taken more and
more into account, the current study designs for AD superfi-
cially address the silent pathogenesis of the disease. The EMA and
FDA are looking forward to qualifying new surrogate endpoints
that encompass appropriate biomarker concepts in support of
a robust biomarker strategy, which would enable the discov-
ery of medicinal products that are active in interfering with AD
pathogenesis.
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